
Celularity (CELU) Stock Forecast & Price Target
Celularity (CELU) Analyst Ratings
Bulls say
Celularity Inc’s focus on developing innovative placental-derived cell therapies positions it favorably within the biotechnology sector, particularly as it targets a range of indications, including cancer and degenerative diseases. The demonstrated efficacy of its product PDA-002, which shows competitive ulcer closure rates compared to existing FDA-approved therapies, underscores the company's potential for significant impact in the wound healing market. Additionally, the bio-banking segment's contribution to the majority of revenues highlights a stable revenue stream that supports the company's ongoing clinical development efforts.
Bears say
Celularity Inc faces significant challenges that could negatively impact its clinical trials and overall business operations, as manufacturing or other failures are likely to affect both the biobanking and degenerative disease segments. Additionally, the decline in natural killer (NK) cell function with age may hinder the effectiveness of their therapies, due to reduced cytokine secretion and decreased target cell cytotoxicity, which could limit market potential. Overall, these operational and biological challenges could substantially undermine investor confidence and adversely affect the company's financial health.
This aggregate rating is based on analysts' research of Celularity and is not a guaranteed prediction by Public.com or investment advice.
Celularity (CELU) Analyst Forecast & Price Prediction
Start investing in Celularity (CELU)
Order type
Buy in
Order amount
Est. shares
0 shares